Recent Quotes

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-10
REV		(EXPECTED)2021-08-10

Q1 2021		Est.		Actual		Surprise
EPS				-0.150
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
NRBO	NeuroBo Pharmaceuticals	2.94	-0.21	-6.66%		70.2M

NeuroBo Pharmaceuticals Frequently Asked Questions

How do I buy NeuroBo Pharmaceuticals (NRBO) stock?

You can purchase shares of NeuroBo Pharmaceuticals (NASDAQ: NRBO) through any online brokerage.

View our list of the best stock brokerages.

Who are NeuroBo Pharmaceuticals's (NRBO) competitors?

Other companies in NeuroBo Pharmaceuticals’s space includes: PolarityTE (NASDAQ:PTE), Allena Pharmaceuticals (NASDAQ:ALNA), Advaxis (NASDAQ:ADXS), Cleveland BioLabs (NASDAQ:CBLI) and Celyad Oncology (NASDAQ:CYAD).

What is the target price for NeuroBo Pharmaceuticals (NRBO) stock?

The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by HC Wainwright & Co. on February 1, 2021. The analyst firm set a price target for 16.00 expecting NRBO to rise to within 12 months (a possible 407.94% upside). 1 analyst firms have reported ratings in the last year.

Current Stock Price for NeuroBo Pharmaceuticals (NRBO)?

The stock price for NeuroBo Pharmaceuticals (NASDAQ: NRBO) is $3.15 last updated Today at 7:45:18 PM.

Does NeuroBo Pharmaceuticals (NRBO) pay a dividend?

There are no upcoming dividends for NeuroBo Pharmaceuticals.

When is NeuroBo Pharmaceuticals (NASDAQ:NRBO) reporting earnings?

NeuroBo Pharmaceuticals’s Q2 earnings are confirmed for after-market on August 10, 2021.

Is NeuroBo Pharmaceuticals (NRBO) going to split?

There is no upcoming split for NeuroBo Pharmaceuticals.

What sector and industry does NeuroBo Pharmaceuticals (NRBO) operate in?

NeuroBo Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.